Oscar Arrieta
Overview
Explore the profile of Oscar Arrieta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
343
Citations
10492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guijosa A, Cabrera-Miranda L, Gomez-Garcia A, Trejo Rosales R, Munoz-Montano W, Flores D, et al.
Oncology
. 2025 Mar;
:1-16.
PMID: 40068665
Introduction: Pleural Mesothelioma (PM) is a rare and aggressive cancer where prognostic assessment is crucial. Traditional prognostic scores such as the European Organisation for Research and Treatment of Cancer (EORTC)...
2.
Saldanha E, Cordeiro de Lima V, Fares A, Corassa M, Gil-Santana L, Arrieta O, et al.
Oncologist
. 2025 Mar;
30(2).
PMID: 40036771
Introduction: ERBB2-mutant non-small cell lung cancer (NSCLC) represents approximately 1%-4% of all lung adenocarcinomas (LUADs) and has emerged as a distinct molecular subtype. Little is known about NSCLC harboring ERBB2...
3.
Gomez-Flores-Ramos L, Brochier M, Stern D, Garcia-Anaya A, Cortes-Valencia A, Jaen J, et al.
Cancer Causes Control
. 2025 Feb;
PMID: 39979770
Purpose: Prospective cohort development in low-resource settings may be limited by cancer registry population coverage; however, information routinely collected in health systems may offer opportunities to advance cancer research. We...
4.
Mountzios G, Saw S, Hendriks L, Menis J, Cascone T, Arrieta O, et al.
Cancer Treat Rev
. 2025 Feb;
134:102902.
PMID: 39978083
The advent of antibody-drug conjugates (ADCs) aims to transform the therapeutic landscape of advanced non-small cell lung cancer (NSCLC). The distinctive architecture of ADCs enables the targeted delivery of highly...
5.
Trejo-Villegas O, Pineda-Villegas P, Armas-Lopez L, Mendoza-Milla C, Peralta-Arrieta I, Arrieta O, et al.
Cancer Gene Ther
. 2025 Feb;
PMID: 39971779
Lung cancer remains the leading cause of cancer-related mortality globally, with genes such as SMARCB1, MEOX2, and GLI-1 playing significant roles in its malignancy. Despite their known involvement, the specific...
6.
Arrieta O, Lozano-Ruiz F, Guijosa A, Soberanis-Pina P, Blake-Cerda M, Gomez-Garcia A, et al.
Front Oncol
. 2025 Feb;
15:1438120.
PMID: 39963102
Background: As survival rates for lung cancer (LC) patients continue to rise, the adverse impacts of therapies become more relevant. Radiotherapy is known to negatively affect bone health. However, radiotherapy-induced...
7.
Herrera-Quiterio G, Valencia-Gonzalez H, de la Cruz-Lopez K, Fernandez-Coto D, Gil J, Marko-Varga G, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940865
The Chromosome-Centric Human Proteome Project (C-HPP) is an international initiative. It aims to create a protein list expressed in human cells by each chromosomal and mitochondrial DNA to enhance our...
8.
Ramos-Ramirez M, Caballe-Perez E, Lucio-Lozada J, Romero-Nunez E, Castillo-Ruiz C, Dorantes-Sanchez L, et al.
Cancer Metastasis Rev
. 2025 Feb;
44(1):30.
PMID: 39915358
Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with non-small cell lung cancer (NSCLC) lacking targetable oncogenic alterations. However, their efficacy in individuals with such genomic alterations remains...
9.
10.
Rios-Garcia E, Guijosa A, Caballe-Perez E, Davila-Dupont D, Izquierdo C, Regino A, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 39904674
Introduction: Brain metastases (BM) are a prevalent and severe complication of non-small cell lung cancer (NSCLC) that significantly affects quality of life. Although several predictive factors for BM have been...